1. Liu J, Lu Y, Wu Q, et al. Mineral arsenicals in traditional medicines: Orpiment, realgar, and arsenolite. J Pharmacol Exp Ther, 2008, 326: 363–368, 10.1124/jpet.108.139543, 1:CAS:528:DC%2BD1cXpsVWru7o%3D, 18463319
2. Chou W C, Chen H Y, Yu S L, et al. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood, 2005, 106: 304–310, 10.1182/blood-2005-01-0241, 1:CAS:528:DC%2BD2MXlvVWjtrg%3D, 15761015
3. Zhou P, Kalakonda N, Comenzo R L. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): Possible mechanisms to explain ATO resistance in vivo. Br J Haematol, 2005, 128: 636–644, 10.1111/j.1365-2141.2005.05369.x, 1:CAS:528:DC%2BD2MXjtVGqsrc%3D, 15725085
4. Park W H, Seol J G, Kim E S, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res, 2000, 60: 3065–3071, 1:CAS:528:DC%2BD3cXjvFOltLo%3D, 10850458
5. Yim E K, Tong S Y, Ho E M, et al. Anticancer effects on TACC3 by treatment of paclitaxel in HPV-18 positive cervical carcinoma cells. Oncol Rep, 2009, 21: 549–557, 1:CAS:528:DC%2BD1MXit1GrtL4%3D, 19148534